Entera Bio develops oral tablet versions of injectable peptide and protein medicines, starting with an osteoporosis candidate. It last closed at $3.00 on Nov 17, down 0.66% on the day. The average 12-month price target from 2 analysts is $10.00 (+233.3% from the last close), with a high of $11.00 and a low of $9.00.
Only 2 firms rated ENTX in the past 90 days, not enough for a consensus
Average 12-month target
$10.00
▲ 233.3% upside
Based on 2 analysts who set a price target on ENTX in the past 90 days. The average target is $10.00, with a high of $11.00 and a low of $9.00, compared with the last close of $3.00.
Low $9.00Avg $10.00High $11.00
Blue marker: last close $3.00
Highest target$11.00
Average target$10.00
Lowest target$9.00
Latest rating changes
GuggenheimInitiated
Sep 25Buy$11
Leerink PartnersInitiated
Sep 18Buy$9
Date
Firm
Action
Rating
Price target
Sep 25
Guggenheim
Initiated
Buy
$11
Sep 18
Leerink Partners
Initiated
Buy
$9
Loading…
Technical Analysis
ENTX · as of the Nov 17 close · updated after every close
Uptrend
The stock sits between its 20 and 50 day averages. It is 33% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 49). The nearest support is the Pivot S1 at $2.97, and the nearest resistance the Pivot at $3.03.
Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityLow, 6.1%/day
Key levels
$4.2052 week high+40.0%
$3.10Swing high (Aug 10)+3.3%
$3.0920 day average+3.0%
$3.06Pivot R1+2.0%
$3.03Pivot+1.0%
$3.00Last close
$2.97Pivot S1−1.0%
$2.9050 day average−3.3%
$2.90Swing low (Nov 5)−3.3%
$2.74100 day average−8.7%
$2.00200 day average−33.3%
$0.9152 week low−69.7%
Indicators
RSI (14)
48.71
Middle of its range
Neutral
MACD
0.06
Below its signal line
Bearish
Stochastic
27.2
Middle of its range
Neutral
ADX (14)
29.4
Trending up
Williams %R
-83.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-44.1
Oversold below −100, overbought above 100
Neutral
Rate of change
−1.6%
Change over 10 sessions
Bearish
ATR (14)
$0.18
Typical daily range, 6.1% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
Uptrend
Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityNormal, 14.3%/day
Key levels
$4.2052 week high+40.0%
$3.10Swing high (Aug 10)+3.3%
$3.0920 day average+3.0%
$3.06Pivot R1+2.0%
$3.03Pivot+1.0%
$3.00Last close
$2.97Pivot S1−1.0%
$2.9050 day average−3.3%
$2.90Swing low (Nov 5)−3.3%
$2.74100 day average−8.7%
$2.00200 day average−33.3%
$0.9152 week low−69.7%
Indicators
RSI (14)
61.26
Strong, overbought above 70
Neutral
MACD
0.33
Below its signal line
Bearish
Stochastic
57.4
Middle of its range
Neutral
ADX (14)
55.8
Strong uptrend
Williams %R
-50.0
Oversold below −80, overbought above −20
Neutral
CCI (20)
50.3
Oversold below −100, overbought above 100
Neutral
Rate of change
+5.6%
Change over 10 sessions
Bullish
ATR (14)
$0.43
Typical daily range, 14.3% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for ENTX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ENTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow ENTX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ENTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ENTX is in one of them and how their past ENTX trades turned out.
Entera Bio is a clinical stage company developing oral tablet versions of peptide and protein medicines that are usually given by injection. Its most advanced product candidate, EB613, is an oral form of teriparatide being studied as a treatment for osteoporosis, a condition that weakens bones and raises fracture risk. The company's N-Tab platform is designed to help these medicines survive digestion and pass into the bloodstream. Entera is based in Jerusalem and targets patients and healthcare providers.